Evidence map›Paper›PMID 36439216›Full record

ReviewFrontiers in cellular and infection microbiology2022

The lncRNAs involved in regulating the RIG-I signaling pathway.

Jing Liu, Qinglu Ji, Feng Cheng, Dengwang Chen, Tingting Geng, Yueyue Huang, Jidong Zhang, Yuqi He, Tao Song

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jing LiuDepartment of Immunology, Zunyi Medical University, Zunyi, China.
Qinglu JiSchool of Pharmacy, Zunyi Medical University, Zunyi, China.
Feng ChengDepartment of Immunology, Zunyi Medical University, Zunyi, China.
Dengwang ChenDepartment of Immunology, Zunyi Medical University, Zunyi, China.
Tingting GengDepartment of Immunology, Zunyi Medical University, Zunyi, China.
Yueyue HuangDepartment of Immunology, Zunyi Medical University, Zunyi, China.
Jidong ZhangDepartment of Immunology, Zunyi Medical University, Zunyi, China.
Yuqi HeSchool of Pharmacy, Zunyi Medical University, Zunyi, China.
Tao SongDepartment of Immunology, Zunyi Medical University, Zunyi, China.
Zunyi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Understanding the targets and interactions of long non-coding RNAs (lncRNAs) related to the retinoic acid-inducible gene-I (RIG-I) signaling pathway is essential for developing interventions, which would enable directing the host inflammatory response regulation toward protective immunity. In the RIG-I signaling pathway, lncRNAs are involved in the important processes of ubiquitination, phosphorylation, and glycolysis, thus promoting the transport of the interferon regulatory factors 3 and 7 (IRF3 and IRF7) and the nuclear factor kappa B (NF-κB) into the nucleus, and activating recruitment of type I interferons (IFN-I) and inflammatory factors to the antiviral action site. In addition, the RIG-I signaling pathway has recently been reported to contain the targets of coronavirus disease-19 (COVID-19)-related lncRNAs. The molecules in the RIG-I signaling pathway are directly regulated by the lncRNA-microRNAs (miRNAs)-messenger RNA (mRNA) axis. Therefore, targeting this axis has become a novel strategy for the diagnosis and treatment of cancer. In this paper, the studies on the regulation of the RIG-I signaling pathway by lncRNAs during viral infections and cancer are comprehensively analyzed. The aim is to provide a solid foundation of information for conducting further detailed studies on lncRNAs and RIG-I in the future and also contribute to clinical drug development.

Indexed as

COVID-19Interferon Type IRNA, Long NoncodingHumansSignal TransductionUbiquitinationInterferon Type IRNA, Long NoncodingantitumorantiviralCOVID-19IFNslncRNAsRIG-I

Identifiers

PMID36439216
PMCPMC9682092
OpenAlexW4308723732

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.